ACMSY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Accustem Sciences Limited engages in the genomic signature-based assay business for the prognosis of early and late recurrence of ER+/HER2 breast cancer in early stage breast cancer patients...

Stats
Today's Volume	1 220.00
Average Volume	18 163.00
Market Cap	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0380 (28.15%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-30	Cerrone Gabriele M	Buy	5 000	Common Stock
2022-12-02	Cerrone Gabriele M	Buy	3 729	Common Stock
2022-11-18	Cerrone Gabriele M	Buy	24 500	Common Stock
2021-12-01	Simon Willy Jules	Sell	0	Common Stock
2021-08-01	Simon Willy Jules	Sell	1 464	Option (right to buy)

INSIDER POWER
100.00
Last 13 transactions
Buy: 33 229 \| Sell: 601 665

AccuStem Sciences Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AccuStem Sciences Limited Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.340

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0527

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0329

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.220

Financial Reports:

No articles found.

AccuStem Sciences Limited

Accustem Sciences Limited engages in the genomic signature-based assay business for the prognosis of early and late recurrence of ER+/HER2 breast cancer in early stage breast cancer patients. The company was incorporated in 2020 and is based in London, the United Kingdom.